{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:51:16Z","timestamp":1784332276118,"version":"3.55.0"},"reference-count":79,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Raynaud's phenomenon (RP) is a common vasospastic condition that results in digital hypoperfusion in response to cold and\/or emotional stress and is associated with significant pain and disability. The aim of our review is to provide a practical approach for clinicians to inform assessment and management of patients with RP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Autoantibodies and nailfold capillaroscopy are key investigations to stratify the risk of progression to systemic sclerosis (SSc) in patients RP, which was recently confirmed in the multicenter, very early diagnosis of systemic sclerosis (VEDOSS) project. Research has explored the complex lived-patient experience of RP including digital vasculopathy in SSc and has highlighted the need for outcome measure development to facilitate research in the field. Pharmacological treatment strategies vary significantly internationally and there is continued interest in developing surgical approaches.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>We provide a practical and up-to-date approach to inform the assessment and management of patients with RP including guidance on drug initiation and escalation. Calcium channel blockers are first-line treatment and can be initiated by primary care physicians. We also highlight second-line drug therapies used for refractory RP and the potential role for surgical intervention.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000877","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T13:02:02Z","timestamp":1655211722000},"page":"235-244","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Practical management of Raynaud's phenomenon \u2013 a primer for practicing physicians"],"prefix":"10.1097","volume":"34","author":[{"given":"Ahmad","family":"Ramahi","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine"},{"name":"University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hughes","sequence":"additional","affiliation":[{"name":"Tameside Hospital, Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne"},{"name":"Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine"},{"name":"University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMra1507638","article-title":"Raynaud's phenomenon","volume":"375","author":"Wigley","year":"2016","journal-title":"N Engl J Med"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/A:1010758530555","article-title":"The effects of stress, anxiety, and outdoor temperature on the frequency and severity of Raynaud's attacks: the Raynaud's treatment study","volume":"24","author":"Brown","year":"2001","journal-title":"J Behav Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3899\/jrheum.190463","article-title":"Effect of season on Internet searches for information on Raynaud phenomenon","volume":"46","author":"Hughes","year":"2019","journal-title":"J Rheumatol"},{"key":"R4-20250526","first-page":"879","article-title":"Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison","volume":"24","author":"Maricq","year":"1997","journal-title":"J Rheumatol"},{"key":"R5-20250526","first-page":"70","article-title":"Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France","volume":"20","author":"Maricq","year":"1993","journal-title":"J Rheumatol"},{"key":"R6-20250526","first-page":"55","article-title":"Prevalence of Raynaud's phenomenon in the adult New Zealand population","volume":"122","author":"Purdie","year":"2009","journal-title":"N Z Med J"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.berh.2016.04.001","article-title":"Raynaud's phenomenon","volume":"30","author":"Hughes","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.01.020","article-title":"International consensus criteria for the diagnosis of Raynaud's phenomenon","volume":"48\u201349","author":"Maverakis","year":"2014","journal-title":"J Autoimmun"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3899\/jrheum.091117","article-title":"Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease","volume":"37","author":"Chikura","year":"2010","journal-title":"J Rheumatol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7861\/clinmed.2020-0754","article-title":"Raynaud's phenomenon","volume":"20","author":"Haque","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"102458","DOI":"10.1016\/j.autrev.2020.102458","article-title":"Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis","volume":"19","author":"Smith","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/rheumatology\/kev201","article-title":"Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis","volume":"54","author":"Hughes","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.5152\/eurjrheum.2020.19124","article-title":"New perspectives in the imaging of Raynaud's phenomenon","volume":"7","author":"Herrick","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4103\/0019-5154.119946","article-title":"Acrocyanosis: an overview","volume":"58","author":"Das","year":"2013","journal-title":"Indian J Dermatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.emc.2016.12.006","article-title":"Frostbite","volume":"35","author":"Handford","year":"2017","journal-title":"Emerg Med Clin North Am"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ced.13891","article-title":"Review of primary and secondary erythromelalgia","volume":"44","author":"Mann","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cps.2019.12.009","article-title":"Complex regional pain syndrome","volume":"47","author":"Neumeister","year":"2020","journal-title":"Clin Plast Surg"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s10067-020-05023-5","article-title":"A systematic review of internet-based information for individuals with Raynaud's phenomenon and patients with systemic sclerosis","volume":"39","author":"Devgire","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2133.1988.tb03477.x","article-title":"Hand warming as a treatment for Raynaud's phenomenon in systemic sclerosis","volume":"119","author":"Goodfield","year":"1988","journal-title":"Br J Dermatol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","article-title":"Clinical practice. Raynaud's phenomenon","volume":"347","author":"Wigley","year":"2002","journal-title":"N Engl J Med"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/29.2.89","article-title":"The acute effects of cigarette smoking on cutaneous blood flow in smoking and nonsmoking subjects with and without Raynaud's phenomenon","volume":"29","author":"Goodfield","year":"1990","journal-title":"Br J Rheumatol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/rheumatology\/kev002","article-title":"Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception","volume":"54","author":"Hughes","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/acr.24710","article-title":"Factors influencing patient decision-making concerning treatment escalation in Raynaud's phenomenon secondary to systemic sclerosis","volume":"73","author":"Hughes","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/rheumatology\/kez522","article-title":"Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?","volume":"59","author":"Hughes","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s10067-021-05598-7","article-title":"How do patients define Raynaud's phenomenon? Differences between primary and secondary disease","volume":"40","author":"Murphy","year":"2021","journal-title":"Clin Rheumatol"},{"key":"R29-20250526","article-title":"Calcium channel blockers for primary and secondary Raynaud's phenomenon","volume":"12","author":"Rirash","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"483","DOI":"10.18433\/J3TC7V","article-title":"An old drug for a new application: potential benefits of sildenafil in wound healing","volume":"15","author":"Farsaie","year":"2012","journal-title":"J Pharm Pharm Sci"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/ard.2009.116475","article-title":"Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study","volume":"69","author":"Brueckner","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/03009742.2011.569755","article-title":"Oral sildenafil in skin ulcers secondary to systemic sclerosis","volume":"40","author":"Della Rossa","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3899\/jrheum.090270","article-title":"Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis","volume":"36","author":"Schiopu","year":"2009","journal-title":"J Rheumatol"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinternmed.2012.2271","article-title":"Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study","volume":"172","author":"Caglayan","year":"2012","journal-title":"Arch Intern Med"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.30195","article-title":"Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis","volume":"63","author":"Herrick","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1742-1241.2006.01049.x","article-title":"Comparison of phosphodiesterase type 5 (PDE5) inhibitors","volume":"60","author":"Wright","year":"2006","journal-title":"Int J Clin Pract"},{"key":"R41-20250526","first-page":"S872","article-title":"Efficacy of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis: a double-blind randomized placebo-controlled parallel group multicentric study","volume":"62","author":"Agarwal","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1997.00219.x","article-title":"The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon","volume":"242","author":"Pancera","year":"1997","journal-title":"J Intern Med"},{"key":"R44-20250526","first-page":"232","article-title":"Prophylactic ACE inhibitor therapy in Raynaud's phenomenon: helpful or harmful? In: Novel insights into systemic sclerosis management","author":"Hughes","year":"2013","journal-title":"Future Medicine"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/pr.111.004697","article-title":"Serotonin and blood pressure regulation","volume":"64","author":"Watts","year":"2012","journal-title":"Pharmacol Rev"},{"key":"R46-20250526","first-page":"14","article-title":"Fluoxetine: clinical pharmacology and physiologic disposition","volume":"46","author":"Lemberger","year":"1985","journal-title":"J Clin Psychiatry"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"R48-20250526","article-title":"Prazosin for Raynaud's phenomenon in progressive systemic sclerosis","volume":"1998","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF00610065","article-title":"Prazosin treatment of primary Raynaud's phenomenon","volume":"24","author":"Nielsen","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archderm.1984.01650390051010","article-title":"A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma","volume":"120","author":"Surwit","year":"1984","journal-title":"Arch Dermatol"},{"key":"R51-20250526","first-page":"94","article-title":"Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study","volume":"12","author":"Russell","year":"1985","journal-title":"J Rheumatol"},{"key":"R52-20250526","doi-asserted-by":"crossref","DOI":"10.1016\/B0-72-169777-1\/50003-2","article-title":"Chapter 1 - The equine immune system","author":"Reed","year":"2004","journal-title":"Equine internal medicine"},{"issue":"(Suppl)","key":"R53-20250526","doi-asserted-by":"crossref","first-page":"S423","DOI":"10.1194\/jlr.R800094-JLR200","article-title":"Prostanoids in health and disease","volume":"50","author":"Smyth","year":"2009","journal-title":"J Lipid Res"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/art.41536","article-title":"Dissecting the cellular mechanism of prostacyclin analog iloprost in reversing vascular dysfunction in scleroderma","volume":"73","author":"Tsou","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.semarthrit.2018.03.019","article-title":"Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus","volume":"48","author":"Ingegnoli","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2133.1982.tb00905.x","article-title":"Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2)","volume":"106","author":"Dowd","year":"1982","journal-title":"Br J Dermatol"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1177\/1060028016660324","article-title":"Evidence for the use of epoprostenol to treat Raynaud's phenomenon with or without digital ulcers","volume":"50","author":"Cruz","year":"2016","journal-title":"Ann Pharmacother"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3109\/03009748609098210","article-title":"Prolonged remission in Raynaud's phenomenon after prostacyclin infusion","volume":"15","author":"Bellucci","year":"1986","journal-title":"Scand J Rheumatol"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0952-3278(88)90118-4","article-title":"Epoprostenol in patients with Raynaud's disease","volume":"33","author":"Fitscha","year":"1988","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2125.1991.tb03883.x","article-title":"Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin","volume":"32","author":"Shawket","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-0038-1650182","article-title":"Successful treatment of Raynaud's Syndrome with prostacyclin","volume":"45","author":"Belch","year":"1981","journal-title":"Thromb Haemost"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"R63-20250526","article-title":"Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis","volume":"1998","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/03009742.2020.1845395","article-title":"Prostanoids in scleroderma microangiopathy: clinical and pharmacoeconomic comparison between two intravenous regimens","volume":"50","author":"Barsotti","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00005344-199509000-00007","article-title":"Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained","volume":"26","author":"Kingma","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/art.40242","article-title":"Efficacy and safety of selexipag in adults with Raynaud's phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study","volume":"69","author":"Denton","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R67-20250526","first-page":"1788","article-title":"A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia","volume":"30","author":"Kotsis","year":"2003","journal-title":"J Rheumatol"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1558944717715119","article-title":"Extended periarterial sympathectomy: evaluation of long-term outcomes","volume":"13","author":"Pace","year":"2018","journal-title":"Hand (N Y)"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/micr.22379","article-title":"Surgical treatment of systemic sclerosis\u2014is it justified to offer peripheral sympathectomy earlier in the disease process?","volume":"35","author":"Momeni","year":"2015","journal-title":"Microsurgery"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2362.2004.01324.x","article-title":"Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study","volume":"34","author":"Sycha","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.prs.0000244860.00674.57","article-title":"Management of vasospastic disorders with botulinum toxin A","volume":"119","author":"Van Beek","year":"2007","journal-title":"Plast Reconstr Surg"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/1753193413516242","article-title":"A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma","volume":"39","author":"Uppal","year":"2014","journal-title":"J Hand Surg Eur Vol"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"e14182","DOI":"10.1111\/dth.14182","article-title":"Botulinum toxin type A in the treatment of Raynaud's phenomenon","volume":"33","author":"Habib","year":"2020","journal-title":"Dermatol Ther"},{"key":"R74-20250526","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00296-020-04606-4","article-title":"Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience","volume":"41","author":"Nagarajan","year":"2021","journal-title":"Rheumatol Int"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.semarthrit.2016.05.001","article-title":"Differential diagnosis of critical digital ischemia in systemic sclerosis: report of five cases and review of the literature","volume":"46","author":"Sharp","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R76-20250526","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamadermatol.2021.1463","article-title":"A practical approach to the management of digital ulcers in patients with systemic sclerosis: a narrative review","volume":"157","author":"Hughes","year":"2021","journal-title":"JAMA Dermatol"},{"key":"R77-20250526","first-page":"5","article-title":"Procedural pain management in the treatment of scleroderma digital ulcers","volume":"33","author":"Giuggioli","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/acr.23475","article-title":"Multinational qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis","volume":"70","author":"Pauling","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R79-20250526","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/acr.24127","article-title":"Multicenter qualitative study exploring the patient experience of digital ulcers in systemic sclerosis","volume":"72","author":"Hughes","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:17:01Z","timestamp":1748294221000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000877","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]}}}